Abstract
e16519Background: Immunotherapy checkpoint inhibitors (CPIs) have improved outcomes for mUC, but response rates are low (15-21%) in platinum-resistant cases. Better biomarkers of CPI treatment resp...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
